CordenPharma acquires AmbioPharm to scale global peptide manufacturing
What's the deal? CordenPharma, a Basel-based contract development and manufacturing organisation (CDMO), has agreed to acquire AmbioPharm, a US-headquartered peptide CDMO with roughly 400 employees across facilities in North Augusta, South Carolina and Shanghai, China.
The deal expands CordenPharma's peptide active pharmaceutical ingredient (API) manufacturing footprint to three continents. AmbioPharm brings advanced synthesis capabilities — including solid-phase, liquid-phase, and hybrid approaches — that complement CordenPharma's existing platform.
AmbioPharm's South Carolina site adds purification and lyophilisation capacity, while its Shanghai campus offers a new state-of-the-art facility for clinical and commercial peptide supply. Combined with CordenPharma's existing Colorado site, the acquisition gives the company fully US-based peptide API supply options alongside a new Asian production node.
AmbioPharm's shareholders will reinvest into the combined business, signalling confidence in the long-term growth potential. Financial terms were not disclosed.
Why now? Demand for complex peptide APIs has surged, driven largely by the explosion of GLP-1-based therapies for obesity and diabetes. CDMOs with large-scale peptide manufacturing capacity are in high demand, and CordenPharma — which has been investing heavily in its peptide platform since private equity firm Astorg acquired it in 2022 — is racing to meet that need.
Adding US and China-based capacity also hedges against supply chain disruptions and offers customers regional flexibility at a time when geopolitical tensions are reshaping pharmaceutical sourcing strategies.
What could go wrong? Integrating two sites across different continents and regulatory regimes is never simple. The Shanghai facility introduces exposure to US-China trade friction, which could complicate things for customers seeking to avoid geopolitical risk rather than embrace it.
The peptide CDMO market is also getting crowded. Several competitors are expanding capacity simultaneously, raising the possibility of oversupply once current demand peaks.
The signal: This deal reflects a broader consolidation wave in the peptide CDMO space. As blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly drive unprecedented peptide demand, contract manufacturers are scaling aggressively through M&A rather than relying solely on organic growth.
The reinvestment by AmbioPharm's shareholders suggests the market views peptide manufacturing as a long-duration bet, not a short-term cycle. Expect more deals like this as CDMOs jockey for position in one of pharma's fastest-growing segments.
Read more: pr.thembnews.com
